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Aims Creatine buffers cellular adenosine triphosphate (ATP) via the creatine kinase reaction. Creatine levels are reduced
in heart failure, but their contribution to pathophysiology is unclear. Arginine:glycine amidinotransferase (AGAT) in
the kidney catalyses both the first step in creatine biosynthesis as well as homoarginine (HA) synthesis. AGAT-/-
mice fed a creatine-free diet have a whole body creatine-deficiency. We hypothesized that AGAT-/- mice would
develop cardiac dysfunction and rescue by dietary creatine would imply causality.
....................................................................................................................................................................................................
Methods
and results
Withdrawal of dietary creatine in AGAT-/- mice provided an estimate of myocardial creatine efflux of 2.7%/day; how-
ever, in vivo cardiac function was maintained despite low levels of myocardial creatine. Using AGAT-/- mice naı̈ve to
dietary creatine we confirmed absence of phosphocreatine in the heart, but crucially, ATP levels were unchanged.
Potential compensatory adaptations were absent, AMPK was not activated and respiration in isolated mitochondria
was normal. AGAT-/- mice had rescuable changes in body water and organ weights suggesting a role for creatine as a
compatible osmolyte. Creatine-naı̈ve AGAT-/- mice had haemodynamic impairment with low LV systolic pressure and
reduced inotropy, lusitropy, and contractile reserve. Creatine supplementation only corrected systolic pressure despite
normalization of myocardial creatine. AGAT-/- mice had low plasma HA and supplementation completely rescued all
other haemodynamic parameters. Contractile dysfunction in AGAT-/- was confirmed in Langendorff perfused hearts
and in creatine-replete isolated cardiomyocytes, indicating that HA is necessary for normal cardiac function.
....................................................................................................................................................................................................
Conclusions Our findings argue against low myocardial creatine per se as a major contributor to cardiac dysfunction.
Conversely, we show that HA deficiency can impair cardiac function, which may explain why low HA is an inde-
pendent risk factor for multiple cardiovascular diseases.
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1. Introduction
The heart has a constant requirement for large amounts of energy in the
form of adenosine triphosphate (ATP) and must maintain the ability to
instantly respond to elevated workloads. Despite this, intracellular ATP
levels do not change in the healthy heart, which implies a tight match
between ATP demand and supply via glycolysis and oxidative phosphor-
ylation.1 The creatine kinase (CK) phosphagen system is considered key
to this by buffering ATP levels via rapid and reversible transfer of the
phosphoryl group of ATP onto creatine (Cr) to form phosphocreatine
(PCr)2: CrþATP$ PCrþADPþHþ.
In animal models and patients with heart failure, a decrease in total
creatine levels and CK enzymatic activity is consistently observed,
regardless of aetiology.3 For example, in patients with dilated cardiomy-
opathy, the ratio of PCr/ATP is reduced at an early stage of pathology
and correlates with ejection fraction and survival.4 However, despite
decades of research, the exact contribution (i.e. cause or effect) of
reduced creatine to cardiac pathophysiology remains controversial.
Creatine is not synthesized in the cardiomyocyte, but must either be
obtained from dietary sources or biosynthesized from arginine and
glycine in a two-step reaction. The first, catalysed by arginine:glycine ami-
dinotransferase (AGAT) pre-dominantly in the kidney, produces guanidi-
noacetate (GA), which is subsequently methylated by guanidinoacetate
N-methyltransferase (GAMT), mostly in the liver, to form creatine.
Creatine is subsequently absorbed by cardiomyocytes against a large con-
centration gradient via a specific creatine transporter (SLC6A8).2
Previous approaches have studied the effects of creatine depletion
using creatine analogues such as guanidinopropionic acid (b-GPA), which
competes with creatine for cellular uptake, but is a poor substrate for
CK.2 Typically, baseline dysfunction is mild or absent, except at high
workloads.5–10 The GAMT-/- model, too, is in agreement with this gen-
eral pattern, showing only a small reduction in left ventricular (LV) sys-
tolic pressure at baseline, but with impaired contractile reserve.11 The
physiological relevance of this impairment is unclear since GAMT-/- mice
ran just as far and as fast as controls under voluntary and forced running
protocols. Furthermore, following experimental myocardial infarction,
cardiac function and remodelling were not altered in creatine-deficient
GAMT-/- mice.12
Both these approaches have major limitations. On the one hand,
depletion of creatine by b-GPA is very slow, and there is always residual
creatine (typically 10–50%). On the other hand, GAMT-/- mice receiving
a creatine-free diet are completely deficient in creatine, but accumulate
millimolar concentrations of GA, which (as with b-GPA) can potentially
compensate the creatine deficiency by participating in the CK reaction,
albeit at a much reduced velocity.13 There is evidence that high levels of
GA and b-GPA can be toxic or have off-target effects (e.g. inhibition of
the Naþ/Kþ pump14), and it is therefore difficult to know with any cer-
tainty whether the observed effects are due to true creatine deficiency.
For these reasons, the AGAT-/- mouse has been keenly awaited in this
field as a ‘pure’ model of creatine deficiency that might yield definitive
answers. This is exemplified by the skeletal muscle phenotype, which is
much more severe in AGAT-/- than in GAMT-/- mice and was completely
reversed by creatine supplementation.13,15,16
It is known that the AGAT enzyme is also the principle source of
homoarginine (HA) in both humans and mice.17,18 HA is a cationic amino
acid structurally similar to arginine, but with an additional carbon in the
alkyl chain.19 It has no established metabolic role and, until recently, was
assumed to be an incidental by-product of the homologous urea cycle.20
Notably, low plasma HA levels have been associated with increased car-
diovascular risk.21
Here, we present the first description of the cardiac phenotype in
AGAT-/- mice. Withdrawal of dietary creatine allowed us to estimate the
rate of myocardial creatine efflux. We confirm that AGAT-/- mice fed a
creatine-free diet are devoid of creatine and PCr in the heart, and deter-
mined the effect on LV structure and function using MRI. Non-invasive
magnetic resonance relaxometry allowed us to analyse body composi-
tion in detail and to demonstrate rescue by creatine supplementation.
Finally, LV haemodynamic function was assessed under low-creatine
conditions in the absence of potentially confounding guanidino com-
pounds as well as after creatine and HA replenishment.
2. Methods
Detailed methods can be found in the Supplementary material online.
2.1 Animals and ethical statement
This investigation was approved by the Committee for Animal Care and
Ethical Review at the University of Oxford and conforms to the UK Animals
(Scientific Procedures) Act, 1986, incorporating Directive 2010/63/EU of the
European Parliament. Arginine:glycine amidinotransferase knockout mice
(AGAT-/-) have a homozygous knockout of the Gatmtm1.1Isb allele created by
homologous recombination.22 All procedures used mice aged 4–7 months
on a pure C57BL/6J genetic background (backcrossed for >10 generations).
Mice were housed in specific pathogen-free cages and maintained on a 12-h/
12-h light–dark cycle under conditions of controlled temperature
(20–22 C) and humidity. Water and chow were available ad libitum.
2.2 Dietary manipulation of creatine and HA
Since AGAT-/- mice are unable to biosynthesize creatine, the myocardial cre-
atine levels are dependent on dietary intake. Two types of study were per-
formed based on the following diets and summarized in Figure 1: (i) Creatine
withdrawal study: mice were bred and weaned onto a chow supplemented
with creatine monohydrate (0.5%, w/w), then switched to a standard
creatine-free chow at 4–5 months. (ii) Creatine-naı̈ve mice and dietary res-
cue: AGAT-/- mice fed a creatine-free chow throughout development are
termed ‘creatine-naı̈ve’ and have whole-body creatine deficiency. Dietary
creatine was introduced in adulthood by switching to a standard diet with
0.5% (w/w) creatine for either 1 week or 7 weeks. L-Homoarginine hydro-
chloride (HA, Sigma–Aldrich, UK) was added to the drinking water at a con-
centration of 14 mg/L for 10 days.18,23
2.3 In vivo cardiac phenotyping
All in vivo magnetic resonance experiments were carried out under isoflurane
anaesthesia on a 9.4 T (400 MHz) MR system (Agilent Technologies) and
using a quadrature-driven birdcage resonator (Rapid Biomedical) for high-
resolution Magnetic Resonance cine Imaging (cine MRI) and cardiac 1H-MRS.
Haemodynamic measurements in the left ventricle were made under isoflur-
ane anaesthesia using a 1F-miro-tip catheter (Millar, Texas, USA) as previ-
ously described.12 Dobutamine was infused at 16 ng/g BW/min via the jugular
vein as a measure of contractile reserve. Mice were killed by cervical disloca-
tion at the end of the experiments and their organs removed, washed in hep-
arinised saline, blotted, and weighed.
2.4 Isolated perfused heart function
Creatine naı̈ve AGAT-/- (n = 8) and WT (n = 7) mice were anaesthetized
with sodium pentobarbital, hearts rapidly excised, cannulated and perfused in
Langendorff constant pressure mode at 80 mmHg with oxygenated Krebs–
Henseleit buffer at 37 C. LV function was assessed in spontaneously beating
418 K.M.E. Faller et al.
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hearts using a water-filled intraventricular balloon with end-diastolic pressure
set to 6.1 ± 0.7 mmHg.
2.5 Isolated cardiomyocyte function
LV cardiomyocytes were isolated via enzymatic dispersion from WT and
AGAT-/- mice that had been fed a creatine containing diet throughout life.
Cell shortening and re-lengthening velocity were measured under field-
stimulation (3 Hz; 35± 1 C) using a video-edge detection system (IonOptix
Corp). In a sub-set of cardiomyocytes, the [Ca2þ]i transient was measured in
fura-2 loaded (5mmol/L, Molecular Probes) myocytes.
2.6 Biochemistry
High-energy phosphates were measured in isolated perfused hearts by
31P-MRS as previously described.11 Plasma HA levels were quantified in
mouse plasma using a stable isotope dilution assay for LC–MS/MS.24
Creatine and taurine levels were quantified by solution-state 1H-NMR spec-
troscopy in LV tissue (50 mg) from creatine-naı̈ve mice (three AGAT-/- and
three WT, age-matched females, mean 30 weeks). Total citrate synthase,
adenylate kinase (AK) activity, CK activity, and CK isoenzyme composition
were measured in LV homogenates.
2.7 Mitochondrial respiration
Cardiac mitochondria were isolated from creatine-naı̈ve AGAT-/- (n = 8) and
WT (n = 7) and basal respiration assessed with a Clark-type electrode using
the Mitocell S200A Micro Respiratory System (Strathkelvin Instruments,
Motherwell, UK) using glutamate (5 mM), malate (2.5 mM), and Naþ-pyru-
vate (5 mM) as substrates.
2.8 Cardiomyocyte cross-sectional area
Hearts from creatine-naı̈ve mice were fixed in 10% buffered formalin, dehy-
drated, and embedded in paraffin. Eight-micron-thick sections were stained
with Masson’s trichrome and measurements were made on150–200 myo-
cytes per animal.
2.9 Body composition
Body composition was measured in conscious mice using an EchoMRI-100
quantitative magnetic resonance whole body composition analyzer (Echo
Medical Systems, Houston, USA).
2.10 Data analysis
Analysis of haemodynamics, MR data, single cell experiments, and all bio-
chemistry measurements were performed independently and analysed in a
blinded fashion. Data are expressed as mean ± SD unless otherwise stated.
The following statistical tests were used: paired two-tailed t-test for compari-
son of AGAT-/- before and after creatine withdrawal, unpaired two-tailed t-
test for comparison of AGAT-/- vs. WT, Mann–Whitney U test for compari-
son of AGAT-/- vs. WT in cases where normal distribution was violated, 1-
way ANOVA for multiple group comparisons, and 2-way ANOVA to assess
the effect of genotype and treatment on body composition and for compari-
son of the haemodynamic response to dobutamine. For all single cell varia-
bles, analysis was carried out in RStudio using a hierarchical statistical
method.25 In cases where variables was non-normally distributed, data were
logarithmically transformed prior to statistical analysis. Bonferroni’s correc-
tion for multiple comparisons was used throughout this study with a signifi-
cance level of P < 0.05.
3. Results
A. Creatine withdrawal study: Since AGAT-/- mice are dependent
on dietary creatine, we hypothesized that changing to a creatine-free
diet in adulthood would lead to a gradual reduction in myocardial crea-
tine levels to demonstrate whether low creatine, as observed in the fail-
ing heart, can cause cardiac dysfunction per se. Figure 1A shows a
schematic of the experimental protocol.
3.1 Dietary creatine withdrawal leads to
myocardial creatine loss
Myocardial creatine levels were measured non-invasively using 1H-MRS
before and after dietary creatine withdrawal in six adult AGAT-/- mice.
At day 0, myocardial creatine levels were similar to those of WT at
75± 10 nmol/mg protein (cf. 68 ± 5 for WT in Table 1) and were unde-
tectable using 1H-MRS by day 83 (Figure 2A and B). Creatine loss fol-
lowed a clear exponential decay pattern with a calculated constant rate
of 2.7 ± 0.4% of the total creatine pool lost per day. However, residual
creatine was detected by HPLC at day 91 (22.8 ± 2.5 nmol/mg protein),
suggesting that part of the creatine pool may not have been visible on
MR in vivo.
3.2 Creatine withdrawal alters body
weight but not cardiac function
Body weight was stable until day 60 of creatine withdrawal, after which
we observed gradual and persistent weight loss of 0.5% of the initial
body weight per day. After 91 days on a creatine-free diet, mice had lost
14% body weight (P < 0.001), which required the termination of the
AGAT -/-
AGAT -/-
Cr+ diet
from weaning
MRI
Switch to
Cr-free diet
MRI MRI
MRI + haemodynamics
and ssue harvest
Creane-naïve mice and dietary rescue
AGAT -/-
Wild-type
AGAT -/-
AGAT -/-
AGAT -/-
Cr-free diet
from weaning
Creane + diet throughout
3weeks       18w Cr-free diet               25w
Creane-free diet
Creane-free diet
Creane-free diet
Creane-free diet
Creane-free diet
Cr+ diet
1w creane
7weeks creane
10 days HA
Diet controls
Body composion,
Haemodynamics and ssue harvest
Creane withdrawal study
B
A
“Naïve KO”
“1wk Cr KO”
“WT”
“7wk Cr KO”
“HA-KO”
Figure 1 Schematic showing experimental study design. (A) Creatine
withdrawal study: AGAT-/- mice were bred and weaned onto a diet
containing 0.5% creatine (w/w), which was then switched to a standard
creatine-free diet at 18 weeks of age in the experimental group. These
animals received multiple MRI and 1H-MRS examinations before LV
haemodynamics and tissue harvest at 25 weeks of age. (B) Creatine-
naı̈ve mice and dietary rescue: WT and AGAT-/- mice were bred and
weaned onto a standard creatine-free diet for the first 4–5 months of
life. Mice were then either maintained on this creatine-free diet,
switched to a creatine supplemented diet for either 1 or 7 weeks, or
given 14 mg/L of homoarginine for 10 days while maintaining a creatine-
free diet. Wild-type controls were included for all dietary
manipulations.
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experiment for animal welfare reasons (Figure 2C). Cine-MRI examination
during the withdrawal period showed a commensurate reduction in LV
mass, which was 8% lower by the final time point (P < 0.01; Figure 2D).
During this period, there was no change in cardiac function assessed non-
invasively using cine-MRI, that is, ejection fraction and cardiac output
remained stable (see Supplementary material online, Table S1).
In vivo LV haemodynamic measurements were made at the final time
point before and after maximal b-adrenergic stimulation with dobut-
amine (Figure 2E–H). There were no significant differences between
AGAT-/- mice following creatine withdrawal and the control group of
AGAT-/- mice fed creatine throughout the experiments. For example,
LV pressures, parameters of contraction (dP/dtmax), and relaxation
(dP/dtmin) were all indistinguishable from Cr-fed AGAT
-/- controls.
Moreover, contractile reserve, the increase in function observed upon
dobutamine stimulation, which is a sensitive marker for early cardiac dys-
function, was unaltered. Post-mortem data confirmed reduced LV mass
and lung weights in mice withdrawn from Cr compared with the control
group (see Supplementary material online, Table S1).
B. Creatine-naı̈ve mice and dietary rescue: Since cardiac func-
tion was unaffected by dietary creatine withdrawal, we sought to study
the extreme scenario of absolute creatine-deficiency, to determine
whether complete absence of creatine causes cardiac dysfunction. For
these experiments we used AGAT-/- mice from a colony that had always
been maintained on a creatine-free diet (i.e. creatine-naı̈ve). To deter-
mine causality for the observed phenotypes we performed dietary res-
cue experiments as per the schematic in Figure 1B.
3.3 Creatine-naı̈ve AGAT-/- hearts are
devoid of creatine
Hearts were perfused in Langendorff mode for assessment of high-
energy phosphates by 31P-MRS. The complete absence of PCr in
AGAT-/- hearts (Figure 3A and B) was most striking and resulted in ele-
vated inorganic phosphate, while ATP and intracellular pH remained at
normal wild-type (WT) levels (Table 1). Total adenine nucleotides (i.e.
AMPþADPþATP) were unchanged. Determination of total creatine
by HPLC could not resolve a peak above background noise, and we thus
confirmed, using solution state 1H-NMR, that creatine levels were negli-
gible. The cellular osmolyte taurine was elevated by 24% in AGAT-/-
hearts, which may partially compensate for the osmotic stress caused by
creatine deficiency.
3.4 Creatine-naı̈ve hearts do not exhibit
cardiac hypertrophy
Whole-body creatine deficiency resulted in severely reduced body
weight (52% lower), but with a disproportionate reduction in long bone
length (tibial length 4% shorter), which complicated the interpretation of
organ weights. For example, absolute LV weight was significantly lower
in age-matched AGAT-/- mice compared with WT, confirmed when
normalized to tibial length, but is significantly higher than WT when
normalized to body weight (Table 1). We therefore determined the
gene expression of molecular markers of hypertrophy (i.e. ANP, BNP,
b-MHC, a-SA), which were not consistently elevated in AGAT-/- hearts
(one marker was elevated, another one was reduced, and two other
markers were unchanged). Absence of a molecular programme of
hypertrophy was confirmed at the cellular level by histology, with the
myocyte cross-sectional area found to be unaltered (Table 1).
3.5 Creatine-naı̈ve hearts and markers of
energy homeostasis
We analysed the expression of key energy homeostasis enzymes for evi-
dence of compensatory adaptation. The total absence of substrate
resulted in a 2.1-fold up-regulation of creatine transporter gene expres-
sion (P = 0.02), but the activity of CK and the distribution of CK isoen-
zymes were unaltered (Figure 3C and D). AK may also play a phospho-
transfer role in the heart and can compensate for the loss of CK system
function; however, AK activity was also unaltered in creatine-naı̈ve
AGAT-/- hearts (Figure 3E). Phosphorylation of AMP-activated protein
kinase (AMPK) is a common indicator of impaired energetic status, but
AMPK was not activated in the AGAT-/- heart (Figure 3F). This was sur-
prising since previous studies showed AMPK activation in skeletal muscle
from AGAT-/- mice,22 and we therefore sought to confirm this as a posi-
tive control for our own assay. AMPK was indeed activated in skeletal
muscle of our AGAT-/- mice (Figure 3F), indicating a divergence of the
biochemical consequences of creatine depletion in cardiac as compared
with skeletal myocytes. AMPK activation in AGAT-/- skeletal muscle
stimulates the PGC1-a mitochondrial biogenesis pathway and thereby
increases citrate synthase activity (a marker for mitochondrial volume).15
......................................................................................................
Table 1 Metabolites and markers of hypertrophy in WT
and AGAT-/- creatine-naı̈ve hearts
Wild-type AGAT-/-
Cr-naı̈ve
31P-MRS (n¼ 6) (n¼ 4)
PCr (mM) 12.7 ± 2.3 0
ATP (mM) 7.0 ± 0.4 6.9 ± 0.8
Pi (mM) 1.5 ± 0.5 4.1 ± 1.8*
pHi 6.9 ± 0.1 7.0 ± 0.1
HPLC (n¼ 5) (n¼ 5)
Total creatine (nmol/mg protein) 68 ± 5 <12 ± 1
Total adenine nucleotides
(nmol/mg protein)
38 ± 11 42 ± 3
Solution state 1H-NMR (n¼ 3) (n¼ 3)
Creatine (normalized intensity) 92.0 ± 1.1 1.5 ± 0.6****
Taurine (normalized intensity) 0.17 ± 0.02 0.21 ± 0.01*
Post-mortem weights (5M/5F) (5M/5F)
Body weight (g) 28.1 ± 6.1 13.4 ± 2.0***
Tibia length (mm) 17.9 ± 0.6 17.1 ± 0.3**
LV weight (mg) 83 ± 14 61 ± 4***
LV/BWt (mg/g) 2.98 ± 0.28 4.62 ± 0.49***
LV/tibial length (mg/mm) 4.59 ± 0.71 3.56 ± 0.23***
RV weight (mg) 23.5 ± 4.6 15.1 ± 1.7***
Hypertrophic markers (n¼ 9) (n¼ 10)
ANP mRNA (% WT) 100 ± 42 420 ± 198***
BNP mRNA (% WT) 100 ± 28 134 ± 87
b-MHC mRNA (% WT) 100 ± 28 260 ± 335
a-SA mRNA (% WT) 100 ± 57 36 ± 19**
Histology (n¼ 3) (n¼ 3)
Myocyte cross-sectional area (mm2) 198 ± 11 210 ± 70
LV, left ventricle; RV, right ventricle, ANP, atrial natriuretic peptide; BNP, brain
natriuretic peptide; b-MHC, beta myosin heavy chain; a-SA, alpha skeletal actin.
Values are represented as mean ± SD.
*P < 0.05. **P < 0.01. ***P < 0.001. ****P < 0.0001 vs. WT.
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Figure 2 Withdrawal of dietary creatine in AGAT-/- mice reduces body weight and LV mass without affecting haemodynamic function. (A) Myocardial cre-
atine depletion was estimated at 2.7 ± 0.4% of the free creatine pool per day using in vivo 1H-MRS. Data were fitted using a kinetic model of non-enzymatic
degradation, according to the following equation: [Cr]t = [Cr]t=0. e
-kt. (B) Representative 1H-MRS spectra of the same mouse before and after creatine with-
drawal. The creatine peak (arrow) seen at day 0 is not visible by day 83. (C) Body weight decreased rapidly after 70 days of creatine-free diet (n = 6). (D) LV
mass calculated by in vivo cine-MRI falls during dietary creatine withdrawal. LV haemodynamic parameters were measured at day 90 in AGAT-/- mice with
and without dietary creatine withdrawal (n = 6/group) under resting baseline conditions and with IV infusion of dobutamine. There were no significant differ-
ences between groups for (E) heart rate, (F) LV end-systolic pressure, (G) the rate of pressure rise maximum (dP/dtmax) as a measure of contractility, or
(H) the rate of pressure rise minimum (dP/dtmin) as a measure of relaxation. Comparison was made by two-way repeated measures ANOVA and data are
represented as mean ± SD.
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Figure 3 Absence of phosphocreatine (PCr) in creatine-naı̈ve AGAT knockout mice does not alter key metabolic parameters in the heart.
Representative 31P-magnetic resonance spectra in Langendorff-perfused hearts. PCr was the most prominent peak in hearts from wild-type mice (A), but
was completely absent in hearts from creatine-naı̈ve AGAT-/- mice (B), where inorganic phosphate (Pi) was elevated, and there was no change in ATP
(appears as three peaks representing the c, a, and b phosphoryl groups). Key energy homeostasis enzymes and mitochondrial function were not significantly
different between wild-type (WT) and creatine-naı̈ve AGAT-/- (KO) hearts. (C) Total creatine kinase (CK) activity and percentage isoenzyme distribution
(D), where Mito is mitochondrial CK and the various dimers of Muscle and Brain isoforms; (E) adenylate kinase (AK) activity (all n = 10 WT, n = 13 KO). (F)
AMPK activation expressed as the ratio of phospho- to total AMPK protein expression was not altered in LV, but was significantly elevated in hind-limb skel-
etal muscle, n = 5 per group. (G) Citrate synthase activity (n = 10 WT, n = 13 KO) and (H) mitochondrial respiration with glutamate (5 mM), malate (2.5 mM)
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In agreement with the lack of AMPK activation in heart, we observed
no change in citrate synthase activity in cardiac muscle of AGAT-/-
(Figure 3G). Furthermore, there was no difference in baseline or ADP-
stimulated respiration in mitochondria isolated from WT and AGAT-/-
hearts (Figure 3H).
3.6 Creatine-naı̈ve mice have altered body
composition
Body composition measured non-invasively by MR relaxometry showed
that AGAT-/- mice had significantly lower lean mass and markedly
reduced body fat and water content (Figure 4A). The relationship
between percentage fat and water was highly linear over a wide range of
body weights,26 as can be seen for WT mice in Figure 4B. For AGAT-/-,
the slope was significantly altered (P < 0.0001), suggesting a fundamental
breakdown in this relationship. To establish the role of creatine on body
composition, we supplemented the diet of AGAT-/- mice with 0.5% crea-
tine monohydrate for 1 week, which is sufficient to normalize tissue lev-
els (e.g. in myocardium [Cr] WT 74± 3 vs. AGAT-/- 70 ± 2 nmol/mg
protein). A 7-week creatine supplementation was also included to deter-
mine the long-term consequences. A further group consisted of
AGAT-/- mice supplemented with 14 mg/L HA added to the drinking
water for 10 days in order to rule out a role for HA deficiency. After
1 week of creatine feeding, the linear relationship between body fat and
water was abolished (slope = 0), whereas the relationship was indistin-
guishable from WT by 7 weeks and unaffected by HA (Figure 4C). Body
composition analysis before and after supplementation showed a rapid
increase in lean mass and body water by 1 week (Figure 4F–G), which is
consistent with creatine having both an ergogenic and osmotic role. A
gain in fat mass was not observed until after 7 weeks (Figure 4E), which
restored the fat-water relationship (Figure 4C). These observations are
likely to provide an explanation for the low post-mortem organ weights
in AGAT-/- mice, which were rescued within one week of creatine sup-
plementation (Figure 5), suggesting that creatine acts as a compatible
osmolyte in the heart and other major organs (i.e. low LV weight is due
to reduced water content).
3.7 Creatine-naı̈ve mice have smaller LV
chamber volumes
WT and creatine-naı̈ve AGAT-/- mice underwent cine-MRI to assess
global structure and function in vivo (see Supplementary material online,
Figure). The difference in LV size is clearly evident in the representative
mid-ventricular short-axis images and is reflected in the low LV mass and
small ventricular end-diastolic and end-systolic volumes in creatine-naı̈ve
AGAT-/- mice. We observed a significant reduction in cardiac output
driven by trends in both heart rate and stroke volume, but with pre-
served ejection fraction. The physiological significance is open to inter-
pretation given the large differences in body weight and composition.
We therefore performed LV haemodynamic measurements, which are
independent of chamber size.
3.8 Creatine-naı̈ve hearts exhibit
haemodynamic impairment
Compared with WT controls, creatine-naı̈ve AGAT-/- mice had a distinct
haemodynamic phenotype consisting of lower LV systolic pressure with
normal end-diastolic pressures and significantly impaired contractility
and relaxation as shown by the reduced rates of pressure rise (dP/dtmax)
and fall (dP/dtmin; Figure 6A–D). Maximal heart rate and dP/dtmax in
response to dobutamine infusion was also lower in AGAT-/- hearts, indi-
cating an impaired contractile reserve (Figure 6E and F).
(i) Creatine rescue: In order to establish causality, we treated mice
with 0.5% dietary creatine, either for 1 week or 7 weeks, to determine
whether this would rescue the in vivo phenotype. WT control mice were
included for each treatment group, but did not differ in any haemody-
namic parameter and were therefore combined into a single WT control
group (see Supplementary material online, Table S2).
In AGAT-/- mice, creatine supplementation corrected myocardial cre-
atine levels within one week (Figure 6G), normalized LV end-systolic
pressure, and increased end-diastolic pressure (Figure 6A and B). This
may reflect the osmotic effect of acute creatine replacement to increase
muscle tone, because there was no apparent effect on functional param-
eters. For example, correcting creatine levels had no effect on either the
inotropic or lusitropic deficits, or on contractile reserve.
(ii) HA rescue: Since creatine supplementation of AGAT-/- mice did
not fully rescue the cardiac phenotype and AGAT-/- mice were also char-
acterized by low HA plasma levels, we included a further group where
we supplemented with HA via drinking water. Plasma HA levels were
low in AGAT-/- mice and were significantly elevated after 10 days of oral
supplementation (Figure 6H). Surprisingly, all inotropic and lusitropic
parameters (i.e. dP/dtmax, dP/dtmin and response to dobutamine) were
rescued by HA supplementation (Figure 6C–F).
(iii) Isolated perfused heart: The presence of cardiac dysfunction
in creatine-naı̈ve AGAT-/- mice was confirmed ex vivo in Langendorff-
perfused hearts (Figure 7A–D), suggesting that dysfunction is an intrinsic
property and not secondary to altered loading conditions or differences
in whole-body composition or metabolism.
3.9 HA deficiency impairs cardiomyocyte
function
We sought to confirm the in vivo and ex vivo findings at the single cardio-
myocyte level. For this we used WT and AGAT-/- mice that had been fed
a creatine-supplemented diet throughout life, i.e. a pure HA-deficiency
without the potentially confounding effects of low creatine on cellular
osmolarity, haemodynamic loading, and whole body metabolism. HA-
deficient cardiomyocytes showed a modest reduction in fractional short-
ening with significantly reduced shortening and re-lengthening velocities
(Figure 7E–H), suggesting that low HA levels per se can impair cardiomyo-
cyte function. This was not associated with changes in [Ca2þ]i transient
amplitude, the time constant of [Ca2þ]i transient decay (tau), or intracel-
lular diastolic calcium levels (Figure 7I–L). See Supplementary material
online, Table S3 for details of statistical analysis.
4. Discussion
We used AGAT-/- mice to study, for the first time, the cardiac conse-
quences of absolute creatine deficiency, i.e. in the absence of other com-
pensatory phosphagens. Our results offer multiple novel insights into
myocardial creatine efflux, creatine as a cellular osmolyte, biochemical
divergence between cardiac and skeletal muscle creatine, cardiac HA
and their impact on cardiac function.
4.1 Myocardial creatine loss
Withdrawal of dietary creatine in AGAT-/- mice allowed us to measure
the rate of myocardial creatine efflux for the first time. Degradation of
creatine and PCr to creatinine is a spontaneous, non-enzymatic and irre-
versible process. Creatinine is formed at a constant rate, diffusing into
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Figure 4 Creatine-naı̈ve AGAT-/- mice have low body weight and altered composition rescuable by dietary creatine. (A) Creatine-naı̈ve KO mice had low
body weight associated with reduced water, fat and lean mass (***P < 0.001; n = 14 male and 14 female per group). (B) These changes were not proportional
because the linear relationship between % body fat and % total water was significantly altered in KO mice (P < 0.0001 for slope). Dietary supplementation
with 0.5% creatine for 1 week abolished the fat-water relationship, which was rescued to WT values after 7 weeks of dietary creatine and was unaltered by
homoarginine (HA) supplementation (C). Values for body weight (D), fat mass (E), lean mass (F), and total water (G) in the same mice before and after
1-week and 7-week creatine supplementation or 10-day homoarginine supplementation are shown in WT (open circles) and KO (triangles). Lean mass and
total water were rapidly changing, suggesting an osmotic role for creatine, whereas fat mass only changed with chronic dietary creatine. Each data point rep-
resents mean ± SD for n = 7–10 mice except HA wild-type (n = 4), ** denotes P < 0.01, *** P < 0.001, **** P < 0.0001 compared with pre-treatment values.
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.the blood before being filtered and excreted by the kidneys.2 Starting
from WT levels, a decrease of 2.7% per day in myocardial creatine
content was calculated, which is in close agreement with earlier esti-
mates of whole-body creatine loss of 2% per day.27 Our experiments
had to be terminated after three months of withdrawal due to excessive
body weight loss, which triggered our humane end-point to prevent
unnecessary animal suffering. Residual creatine was therefore present at
the point of phenotyping and previous b-GPA experiments suggest that
cardiac function is only impacted when less than 20–25% creatine
remains.10,28 Nevertheless, final creatine levels were well below that
observed in the failing heart without impacting on in vivo function or con-
tractile reserve. This argues against a causative role for low creatine in
driving contractile dysfunction. It should be noted that the effect of HA
deficiency was not apparent in this experiment because we compared
knockout groups with and without dietary creatine (i.e. both groups
were HA deficient).
4.2 Creatine as compatible osmolyte
Weight loss or low body weight has been a universal finding in creatine
deficiency studies, either due to b-GPA feeding or GAMT-/-, and
creatine-naı̈ve AGAT-/- mice are even more severely affected.22 Our
study was performed using non-invasive MR relaxometry, which allowed
us to examine the effects on body composition before and after creatine
rescue in the same mice. Our results demonstrated that fat mass, lean
mass, and total water were lower in AGAT-/- mice and was rescued by
creatine supplementation. The robust increase in total water was most
notable, occurring within one week of creatine supplementation, which
strongly suggests that creatine acts as an osmolyte in the heart and other
organs, such that replacing cellular creatine also replaces water. In line
with this observation, we found elevated levels of the established osmo-
lyte, taurine, in AGAT-/- hearts, which could represent a partial compen-
sation for the loss of creatine as an osmolyte. The converse was
observed in mice with elevated myocardial creatine, in which taurine lev-
els were negatively correlated with creatine, suggesting a degree of inter-
changeability, i.e. compatible osmolytes.29 This is supported by cell
culture studies in which creatine was as effective as taurine in protecting
cultured muscle cells following exposure to hypertonic media.30 Indeed,
an osmotic effect of creatine is the most likely explanation for the com-
plete normalization of organ weights within one week of creatine
supplementation.
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Figure 5 Creatine-naı̈ve AGAT-/- mice have low vital organ weights that are rapidly rescued by dietary creatine supplementation. Post-mortem blotted
organ weights from left ventricle (A), lung (B), liver (C), and kidney (D) taken from wild-type (WT, n = 29), creatine-naı̈ve knockout (KO, n = 10), and KO
mice supplemented with 0.5% dietary creatine for 1 week (n = 7), 7 weeks (n = 9), or homoarginine (HA) 14 mg/L added to the drinking water (n = 7). Data
are represented as mean ± SD, ** denotes P < 0.01 and ** P < 0.001 compared with WT and ## P < 0.01, ### P < 0.001 compared with creatine-naı̈ve
knockout.
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Figure 6 In vivo haemodynamic measurements in creatine-naı̈ve AGAT-/- (KO) mice shows inotropic and lusitropic deficits rescued by homoarginine but
not by creatine supplementation. (A) LV end-systolic pressure, (B) LV end-diastolic pressure, (C) the rate of pressure rise maximum (dP/dtmax) as a measure
of contractility, (D) the rate of pressure rise minimum (dP/dtmin) as a measure of relaxation. (E) and (F) are heart rate and dP/dtmax, respectively during IV
infusion with dobutamine at 16 ng/g BW/min. WT control and treatment groups did not significantly differ for any of the parameters and were subsumed
into one group (n = 29), all other groups n = 7–10. (G) Supplementation with 0.5% dietary creatine for 1 week normalized myocardial creatine levels
(n = 7–8). (H) Plasma levels of homoarginine were significantly lower in KO (n = 6) vs. WT (n = 6) and are elevated by supplementation via drinking water
(n = 3). All data are represented as mean ± SD, * denotes P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 compared with WT and # P < 0.05,
## P < 0.01, ### P < 0.001, #### P < 0.0001 compared with creatine-naı̈ve knockout.
426 K.M.E. Faller et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article/114/3/417/4721788 by Edinburgh U
niversity user on 25 August 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.4.3 Cardiac adaptations to low creatine
levels
Creatine-naı̈ve mice were bred using heterozygous mating to restrict
the effects on development. This implies that they may have received
small amounts of creatine via the placenta and suckling, but our experi-
ments were performed in adult mice aged >20 weeks in which the
absence of creatine was verified by multiple methods. Post-natal com-
pensatory adaptations have been described even for a relatively short b-
GPA feeding period, among them mitochondrial proliferation31 and
changes in myosin isoenzyme expression associated with ventricular
hypertrophy,6 although these may represent off-target effects of b-GPA.
We cannot completely rule out the development of adaptations in
AGAT-/- hearts, although we did not observe changes in mitochondrial
respiration or citrate synthase activity (a marker of mitochondrial vol-
ume), nor did we observe cardiac hypertrophy at a histological or molec-
ular level. In CK-deficient mice, mitochondrial rearrangement was
described to reduce diffusion distances for high-energy phosphates,32
but detailed analysis of GAMT-/- hearts failed to detect similar alterations
of creatine deficiency.33
Other obvious adaptations were absent, e.g. AK represents an alter-
native phosphotransfer mechanism that is upregulated in CK-deficient
mouse hearts.34 We did not observe changes in AK activity in AGAT-/-
mice, although a definitive answer would require measurements of AK
flux. These findings are in agreement with the GAMT-/- model, where dif-
ferential proteomic analysis did not reveal any potential adaptations.12
Most importantly, we can rule out the contribution of GA participation
0.0 0.1 0.2 0.3
1.2
1.4
1.6
1.8
2.0
2.2
Time (s)
Ca
2+
 T
ra
ns
ie
nt
 A
m
pl
it
ud
e
(F
ur
a-
2 
ra
ti
o)
WT
AGAT KO
WT AGAT KO 
0.0
0.5
1.0
1.5
2.0
D
ia
s
to
li
c
 [
C
a
2
+
] i
(F
u
ra
-2
 r
a
ti
o
)
P=0.58
WT AGAT KO 
0.0
0.5
1.0
1.5
2.0
C
a
2
+
 T
ra
n
s
ie
n
t 
A
m
p
li
tu
d
e
(F
/F
0
)
P=0.86
WT AGAT KO
0
200
400
600
R
e
-l
e
n
g
th
e
n
in
g
 v
e
lo
c
it
y
 (
μμm
/s
e
c
)
P=0.009
WT AGAT KO
0
100
200
300
400
500
H
e
a
rt
 R
a
te
 (
B
P
M
)
P=0.18
WT AGAT KO
0
200
400
600
S
h
o
rt
e
n
in
g
 V
e
lo
c
it
y
 (
μm
/s
)
P=0.030
2
4
6
8
AGAT KO
WT
Fr
ac
ti
on
al
 S
ho
rt
en
in
g 
(%
)
WT AGAT KO
0
2
4
6
8
10
12
14
F
ra
c
ti
o
n
a
l 
S
h
o
rt
e
n
in
g
 (
%
) P=0.08E
WT AGAT KO
0
20
40
60
80
100
L
V
 D
e
v
e
lo
p
e
d
 p
re
s
s
u
re
(m
m
H
g
)
P=0.08
HGF
WT  AGAT KO
0
20
40
60
80
100
L
V
 s
y
s
to
li
c
 p
re
s
s
u
re
(m
m
H
g
)
P=0.04
WT AGAT KO
0
10000
20000
30000
40000
R
a
te
 P
re
s
s
u
re
 P
ro
d
u
c
t
(m
m
H
g
.b
p
m
)
P=0.03A B C D
I J LK
WT AGAT KO   
0
50
100
150
ta
u
 (
m
s
)
P=0.93
Figure 7 Contractile dysfunction is confirmed ex vivo in creatine-naı̈ve hearts and a role for homoarginine-deficiency is confirmed in creatine-replete iso-
lated cardiomyocytes. Hearts perfused in Langendorff mode from wild-type (WT; n = 7) and creatine naı̈ve AGAT-/- mice (KO; n = 8) showing (A) Left ven-
tricular end-systolic pressure, (B) LV developed pressure, (C) Heart rate, (D) Rate pressure product. Mean values± SD with * denoting P < 0.05 by two-way
unpaired t-test. Cardiomyocytes were isolated from WT and AGAT-/- mice supplemented with 0.5% dietary creatine (i.e. homoarginine deficiency only). (E)
Averaged cell shortening recording in field-stimulated (3 Hz, 35 C) LV myocytes. (F) AGAT-/- cardiomyocytes show a trend for impaired fractional shorten-
ing and (G, H) slower shortening and re-lengthening kinetics compared with WT cardiomyocytes (n = 106/97 cells from seven hearts per genotype). This
occurred in the absence of differences in [Ca2þ]i transient amplitude (I, J) the decay constant of the [Ca
2þ]i transient (tau) (K) or in diastolic Ca
2þ levels (L)
(n = 51/53 cells from 6/6 hearts per genotype). Data are represented as median (IQR), P values were calculated by hierarchical statistical analysis on normally
distributed data or on logarithmic transformed data (as indicated in Supplementary material online, Table S3).
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to the CK reaction as a compensatory mechanism for the GAMT-/- car-
diac phenotype.
4.4 Skeletal vs. cardiac muscle phenotype
In contrast to the heart, AGAT-/- mice have severe muscular dystrophy
manifesting as skeletal muscle atrophy, abnormal mitochondria, and
reduced grip strength, all of which were completely rescued by creatine
supplementation.15 The fundamental difference appears to be that ATP
is maintained at normal levels in the heart, but was 46% lower in skeletal
muscle.15 Unsurprisingly, this energetic deficit leads to the activation of
AMPK, which we confirmed in skeletal muscle, but which was absent in
cardiac muscle within the same animals. AMPK is an important energy
sensor acting to switch off energy-demanding processes and activating
energy-saving and production-related pathways,35 as demonstrated by
multiple changes in metabolic gene expression observed in AGAT-/- skel-
etal muscle.36 One downstream consequence is the stimulation of mito-
chondrial biogenesis via the PGC1-a pathway, which resulted in an
elevation of the citrate synthase activity by 70% in skeletal muscle,15 but
we did not observe any changes in the heart. This demonstrates a major
divergence in the biochemical consequences of creatine depletion in
skeletal vs. cardiac muscle, perhaps reflecting higher mitochondrial cell
density and capacity for oxidative phosphorylation in cardiomyocytes,37
making them less reliant on the CK system to maintain ATP. That PCr
levels are considerably higher in skeletal muscle,2 supports the view of a
relatively CK-dependent tissue, whereas the heart is too important to
fail and therefore displays greater metabolic redundancy.
A comparison of the skeletal muscle phenotype with GAMT-/-, too,
provides valuable insight. GAMT-/- mice do not have overt muscle weak-
ness and can run just as far and as fast as WT controls.12 GA, the creatine
precursor, has been shown to accumulate in both muscle types, where it
can be phosphorylated by the CK reaction.11,13 Apparently, this is suffi-
cient to compensate for creatine deficiency in skeletal muscle, hence the
severe phenotype when GA is absent in AGAT-/-. In contrast, both
GAMT-/- and AGAT-/- hearts show impaired contractile reserve,11 but
this reflects HA deficiency in AGAT-/-. As GAMT-/- mice are not HA
deficient,18 it may be possible that GA accumulation accounts for the
limited contractile reserve in this model, e.g. by inhibition of the Naþ/Kþ
pump.14
4.5 Myocardial creatine is unnecessary to
support baseline cardiac function
We did not observe any baseline dysfunction in creatine-naı̈ve AGAT-/-
mice by cine-MRI, and this is in broad agreement with the earlier ana-
logue feeding studies in which baseline dysfunction was found to be
either relatively mild (e.g.5–7) or completely absent (e.g.8–10), with dys-
function becoming apparent or exacerbated at higher workloads. The
GAMT-/- model, too, is in agreement with this general pattern, showing
normal function by cine-MRI and only a small reduction in LV systolic
pressure at baseline.11 Our findings in AGAT-/- mice do not include
potentially confounding effects of b-GPA or GA accumulation and sup-
port the concept that a fully functioning CK system is not required to
maintain baseline cardiac function. Furthermore, we show that low crea-
tine on its own is insufficient to drive cardiac dysfunction.
It is a limitation that our model is a global knockout, however this is
unavoidable, since AGAT is predominately expressed in the kidney but
not in the normal heart,38 so a cardiac-specific AGAT-/- would be unin-
formative since creatine and HA are both taken up from the circulation.
This means our in vivo haemodynamic phenotype could be confounded
by changes in body composition, loading conditions and whole-body
metabolism. For example, reduced dP/dtmax in creatine-naı̈ve mice may
have resulted from reduced load rather than from altered contractility.
However, the fact that cardiac dysfunction in the creatine-naı̈ve knock-
out persists in the ex vivo perfused heart, where loading conditions and
metabolic substrates are controlled, strongly argues against whole-body
confounders. Furthermore, we observed slower contraction and relaxa-
tion in isolated cardiomyocytes from HA-deficient (but creatine-replete)
hearts. These experiments also eliminate differences in cellular osmolar-
ity, and suggests that low HA levels per se may contribute to cardiac dys-
function. The magnitude of this effect is relatively modest and these
changes were not explained by consonant changes in intracellular cal-
cium. Our data do not rule out the potential for synergy when both HA
and creatine levels are low.
4.6 HA and cardiac function
It is notable that low circulating HA has been identified as a novel risk fac-
tor for multiple cardio- and cerebrovascular diseases (reviewed in21).
For example, in a prospective study of patients undergoing coronary
angioplasty, low serum HA was independently associated with a higher
risk of all-cause and cardiovascular mortality,20 including stroke, sudden
cardiac death, fatal myocardial infarction, and heart failure, with a positive
correlation between HA levels and ejection fraction.39 Collectively,
these studies indicate that low plasma HA is a biomarker for cardiovas-
cular disease risk, but the linking mechanism has yet to be identified.
Notably, a causal relationship between HA deficiency and ischaemic
stroke has been demonstrated in AGAT-/- mice, which developed larger
cerebral injuries that were rescued by HA supplementation.18
Our analogous findings provide the first evidence that low HA per se
may contribute to impaired in vivo cardiac function, suggesting a potential
role in the pathophysiology of heart disease. This is supported by our
recent study demonstrating that HA supplementation in WT mice with
ischaemic heart failure preserved contractile reserve.23
Our current study may also shed light on why AGAT expression is
up-regulated in the human failing heart.40 Local creatine biosynthesis has
been postulated, but seems unlikely in the absence of commensurate
GAMT expression. An alternative explanation is that compensatory HA
biosynthesis may support contractile function.
Finally, our findings may also be of relevance to patients with AGAT
deficiency syndrome. This rare genetic disorder typically manifests in
childhood as skeletal muscle myopathy and developmental delay, which
responds to early creatine supplementation.41 Cardiac involvement has
not been examined in these patients, but if confirmed to be present, our
study predicts that HA supplementation would be beneficial.
4.7 Conclusions
Our findings represent the strongest evidence to date that a fully func-
tioning CK system is not required for maintaining normal baseline cardiac
function, or for supporting contractile reserve. Indeed, in vivo cardiac dys-
function in AGAT-/- mice is principally driven by HA deficiency rather
than creatine deficiency. This suggests that low HA is more than just a
risk factor for cardiovascular disease, but may play an active role in its
pathophysiology.
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Supplementary material is available at Cardiovascular Research online.
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